M E Lippman

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants
    M E Lippman
    Osteoporosis Research Program, Women s College Hospital, Toronto, Ontario, Canada
    J Clin Oncol 19:3111-6. 2001
  2. ncbi request reprint Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk
    Marc E Lippman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:5242-7. 2006
  3. ncbi request reprint Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'
    Marc E Lippman
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109 0368, USA
    Breast Cancer Res Treat 90:1-3. 2005
  4. ncbi request reprint Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis
    Chandan Kumar-Sinha
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 63:132-9. 2003
  5. pmc The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
    Matthew J Sikora
    Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Breast Cancer Res Treat 115:289-96. 2009
  6. pmc Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors
    Chad J Creighton
    Bioinformatics Program, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Genome Biol 7:R28. 2006
  7. ncbi request reprint EGFR and EGFRvIII expression in primary breast cancer and cell lines
    James M Rae
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0612, USA
    Breast Cancer Res Treat 87:87-95. 2004
  8. ncbi request reprint GREB 1 is a critical regulator of hormone dependent breast cancer growth
    James M Rae
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0612, USA
    Breast Cancer Res Treat 92:141-9. 2005
  9. ncbi request reprint GREB1 is a novel androgen-regulated gene required for prostate cancer growth
    James M Rae
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Prostate 66:886-94. 2006
  10. ncbi request reprint Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors
    James M Rae
    Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
    Breast Cancer Res Treat 83:99-107. 2004

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants
    M E Lippman
    Osteoporosis Research Program, Women s College Hospital, Toronto, Ontario, Canada
    J Clin Oncol 19:3111-6. 2001
    ..To test the hypothesis that risk factors related to lifetime estrogen exposure predict breast cancer incidence and to test if any subgroups experience enhanced benefit from raloxifene...
  2. ncbi request reprint Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk
    Marc E Lippman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:5242-7. 2006
    ..To assess the effect of raloxifene, indicated for osteoporosis treatment and prevention, on invasive breast cancer in subgroups of postmenopausal women defined by risk factors for breast cancer...
  3. ncbi request reprint Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'
    Marc E Lippman
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109 0368, USA
    Breast Cancer Res Treat 90:1-3. 2005
  4. ncbi request reprint Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis
    Chandan Kumar-Sinha
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 63:132-9. 2003
    ..These studies characterize a molecular connection between two genes individually implicated in tumorigenesis but never linked together...
  5. pmc The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
    Matthew J Sikora
    Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Breast Cancer Res Treat 115:289-96. 2009
    ..The generation of estrogen-like steroids represents a potential mechanism of resistance to aromatase inhibitors...
  6. pmc Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors
    Chad J Creighton
    Bioinformatics Program, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Genome Biol 7:R28. 2006
    ....
  7. ncbi request reprint EGFR and EGFRvIII expression in primary breast cancer and cell lines
    James M Rae
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0612, USA
    Breast Cancer Res Treat 87:87-95. 2004
    ..In contrast, EGFRwt was expressed at varying levels in the majority of samples tested. We conclude that the expression of EGFRvIII is extremely rare in breast cancer and therefore it does not contribute to the malignant phenotype...
  8. ncbi request reprint GREB 1 is a critical regulator of hormone dependent breast cancer growth
    James M Rae
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0612, USA
    Breast Cancer Res Treat 92:141-9. 2005
    ....
  9. ncbi request reprint GREB1 is a novel androgen-regulated gene required for prostate cancer growth
    James M Rae
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Prostate 66:886-94. 2006
    ..GREB1 is expressed in the prostate and its putative promoter contains potential androgen receptor (AR) response elements...
  10. ncbi request reprint Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors
    James M Rae
    Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
    Breast Cancer Res Treat 83:99-107. 2004
    ..5 microM or less. However, higher doses (EC50's >or= 2 microM) were needed to block the growth of human tumor cell lines potentially implicating a second site of action for these compounds...
  11. ncbi request reprint Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples
    James M Rae
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, 5323 Med Sci 1, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Pharmacogenetics 13:501-7. 2003
    ..We set out to establish genotyping methods for relevant genes from archival tumor samples and determine if fixation, processing or somatic changes in the tumor might affect our ability to identify germ-line polymorphisms...
  12. pmc An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status
    Marc E Lippman
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Trans Am Clin Climatol Assoc 119:77-90; discussion 90-2. 2008
    ..This combined biological and informatic analysis is potentially applicable to many other cancer therapeutics...
  13. ncbi request reprint Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
    Zaneta Nikolovska-Coleska
    University of Michigan Comprehensive Cancer Center, Departments of Internal Medicine and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109 0934, USA
    J Med Chem 47:2430-40. 2004
    ....
  14. ncbi request reprint Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists
    Shaomeng Wang
    Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Semin Oncol 30:133-42. 2003
    ..In this article we will provide a brief review on the strategy and recent progress in designing small-molecule antagonists targeting Bcl-2 and Bcl-X(L)...
  15. ncbi request reprint (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer
    Liang Xu
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, 5301B Medical Science Research Building III, 1500 West Medical Center Drive, Ann Arbor, MI 48109 0640, USA
    Mol Cancer Ther 4:197-205. 2005
    ..Gossypol may improve the outcome of current prostate cancer radiotherapy and represents a promising novel anticancer regime for molecular targeted therapy of hormone-refractory prostate cancer with Bcl-2/Bcl-xL overexpression...
  16. pmc A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival
    Jianjun Yu
    Bioinformatigram, The University of of Michigan Medical Center, Ann Arbor, MI 48109 USA
    Neoplasia 10:79-88. 2008
    ..Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance...
  17. ncbi request reprint Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses
    Matthew Ellis
    Department of Oncology, Georgetown University School of Medicine, Washington, DC 20007, USA
    Clin Cancer Res 8:1155-66. 2002
    ..We wished to develop optimal tissue acquisition, processing, and analysis procedures for exploring the gene expression profiles of breast core needle biopsies representing cancer and noncancer tissues...
  18. ncbi request reprint Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice
    Angus M Tester
    Victorian Breast Cancer Research Consortium VBCRC Invasion and Metastasis Unit, St Vincent s Institute of Medical Research, Department of Surgery, University of Melbourne, Australia
    Cancer Res 64:652-8. 2004
    ..MMP-2 may be a useful target for breast cancer therapy when refinement of MMP inhibitors provides for MMP-specific agents...
  19. ncbi request reprint Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring
    Leena Hilakivi-Clarke
    Department of Oncology, Lombardi Cancer Center, Washington, DC 20007, USA
    Clin Cancer Res 8:3601-10. 2002
    ....
  20. ncbi request reprint New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK
    Daniel F Hayes
    Breast Cancer Res Treat 100:237-8. 2006
  21. ncbi request reprint Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial
    Matthew M Poggi
    Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Cancer 98:697-702. 2003
    ..After a median potential follow-up of 18.4 years, the authors present the updated results...
  22. ncbi request reprint Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889 5015, USA
    J Clin Oncol 22:4067-74. 2004
    ..To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy...
  23. ncbi request reprint Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients
    Kenneth R Meehan
    Division of Hematology and Oncology, Bone Marrow Transplant Program, Georgetown University Medical Center and the Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
    J Hematother Stem Cell Res 11:415-21. 2002
    ..These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients...
  24. ncbi request reprint Acceptability of diagnostic tests for breast cancer
    Wenchi Liang
    Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20007, USA
    Breast Cancer Res Treat 79:199-206. 2003
    ..To assess the acceptability of new non-invasive breast cancer diagnostic tests intended to triage women in need of biopsy...